NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
BeyondSpring Inc. BYSI
12 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
—
Revenue, FY2025 · full 12-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.0 · Net income -1.0
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2022 · Operating -2756.4% · Net -2685.4%
ROE
FY2022 · ROE -321.5%
The 12-year record
12 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · |
| EPS, diluted $ | · | · | · | · | −1.64 | −2.03 | −1.55 | −2.42 | −4.40 | −0.75 | −0.53 | −0.22 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | −321.5 | −111.6 | −102.8 | −338.4 | −568.3 | −467.8 | −113.8 | −89.1 | · |
| Shares out B | · | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures · 1 divergences in 43 reconciliationsAUDITED
Reconciled in 11 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 33 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures1 divergent
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2014